title: Short-Wavelength Automated Perimetry Parameters at Baseline and Following Remission in Patients With Birdshot Retinochoroidopathy.
abstract: OBJECTIVE
  To identify changes in short-wavelength automated perimetry patterns and parameters between the active and inactive states.
  
  
  METHODS
  Retrospective cohort study with age-matched, normal controls.
  
  
  METHODS
  setting: Private tertiary referral center.
  
  
  METHODS
  Seventy-five eyes of 38 patients with active birdshot retinochoroidopathy and 37 eyes of 37 historical normal controls.
  
  
  METHODS
  Thirty-seven patients received immunomodulatory therapy. A fluocinolone acetonide intravitreal implant (Retisert) was implanted in both eyes of 1 patient as an initial treatment.
  
  
  METHODS
  Changes in short-wavelength automated perimetry total deviation scores, pattern deviation scores, mean deviation, and pattern standard deviation in the active phase and the remission state.
  
  
  RESULTS
  Mean deviation (P = .006), pattern standard deviation (P = .001), total deviation score (P = .002), and pattern deviation score (P = .007) were significantly different from the active phase to the remission state. The length of time required to achieve remission did not significantly affect the changes in mean deviation (regression coefficient = 0.01; P = .92), pattern standard deviation (regression coefficient = 0.01; P = .87), total deviation score (regression coefficient = -0.1; P = .32), or pattern deviation score (regression coefficient = 0.1; P = .36) from the active phase to the remission state.
  
  
  CONCLUSIONS
  There was significant improvement in total deviation score, pattern deviation score, mean deviation, and pattern standard deviation on short-wavelength automated perimetry as patients achieved remission. Short-wavelength automated perimetry appears to be a useful and complementary modality in monitoring disease activity in birdshot retinochoroidopathy.
authors.affiliation: Massachusetts Eye Research and Surgery Institution, Waltham, Massachusetts; Ocular Immunology & Uveitis Foundation, Waltham, Massachusetts.
authors.forename: Arash
authors.initials: A
authors.lastname: Maleki
authors.affiliation: Massachusetts Eye Research and Surgery Institution, Waltham, Massachusetts; Ocular Immunology & Uveitis Foundation, Waltham, Massachusetts.
authors.forename: Robert T
authors.initials: RT
authors.lastname: Swan
authors.affiliation: Massachusetts Eye Research and Surgery Institution, Waltham, Massachusetts; Ocular Immunology & Uveitis Foundation, Waltham, Massachusetts; Department of Ophthalmology, Rajavithi Hospital, College of Medicine, Rangsit University, Bangkok, Thailand.
authors.forename: Sukhum
authors.initials: S
authors.lastname: Silpa-Archa
authors.affiliation: Massachusetts Eye Research and Surgery Institution, Waltham, Massachusetts; Ocular Immunology & Uveitis Foundation, Waltham, Massachusetts.
authors.forename: Janine M
authors.initials: JM
authors.lastname: Preble
authors.affiliation: Department of Statistics, Columbia University, New York, New York.
authors.forename: Yuchen
authors.initials: Y
authors.lastname: He
authors.affiliation: Massachusetts Eye Research and Surgery Institution, Waltham, Massachusetts; Ocular Immunology & Uveitis Foundation, Waltham, Massachusetts; Harvard Medical School, Boston, Massachusetts. Electronic address: sfoster@mersi.com.
authors.forename: C Stephen
authors.initials: CS
authors.lastname: Foster
mesh_terms: D000328:Adult; D000368:Aged; D000080365:Birdshot Chorioretinopathy; D002825:Chorioretinitis / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology*; D004396:Coloring Agents / Q000008:administration & dosage; D004343:Drug Implants; D004596:Electroretinography; D005260:Female; D005446:Fluocinolone Acetonide / Q000008:administration & dosage; D005451:Fluorescein Angiography; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D007208:Indocyanine Green / Q000008:administration & dosage; D007429:Intraocular Pressure; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D014786:Vision Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology*; D014792:Visual Acuity / Q000502:physiology; D058609:Visual Field Tests; D014794:Visual Fields / Q000502:physiology*
chemical_list: D004396:Coloring Agents; D004343:Drug Implants; D005938:Glucocorticoids; D005446:Fluocinolone Acetonide; D007208:Indocyanine Green